Gå ubegrenset med Magzter GOLD

Gå ubegrenset med Magzter GOLD

Få ubegrenset tilgang til over 9000 magasiner, aviser og premiumhistorier for bare

$149.99
 
$74.99/År
The Perfect Holiday Gift Gift Now

Marketing with an enticement, not a mallet : content marketing strategies for startups in biotech

BioSpectrum Asia

|

April 2020

Competing against the industry Goliaths that dominate the health and biotech industries can seem like an impossible task for a company in its infancy. Fortunately, small businesses and startups can build a competitive edge by combining innovation with an organized content marketing campaign. Small business owners simply need to be aware of the key challenges they face and combat those challenges through a strategic content marketing campaign aimed at health and biotech customers.

Marketing with an enticement, not a mallet : content marketing strategies for startups in biotech

Identifying Key Challenges for Startups in the Biotech and Health Arenas

Breaking into the biotech or healthcare industry requires a small business owner to recognize the barriers they face as a small fish in an ocean of large sharks. Not surprisingly, many of these challenges related to difficulties earning the trust of prospective customers:

Establishing trust among customers who are unfamiliar with your brand

Demonstrating your commitment to product quality

Figuring out how to bring energy to cold, lifeless products such as pills and technology

Breaking down complicated product properties into successful selling points

Content Marketing Strategies for Health and Biotech Startups

Fortunately for small business owners, content marketing has the power to enable your business to thrive in spite of its small size and limited resources. The key is to use content marketing to humanize your business and earn customer trust.

Give a face to your company

Let’s face it – health and biotech products are cold, complicated, and lifeless without the people who design them and sell them. Your ‘About Us’ page is often one of the first pages customers will visit when they arrive at your site. This is often because customers instinctively want to feel comfortable and safe with their biotech provider. Follow these steps to help build trust among new customers:

FLERE HISTORIER FRA BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

"The next 5-years will see mRNA science evolve beyond infectious disease"

A new survey from Moderna Singapore reveals persistent vaccine hesitancy among older adults in Singapore, even as international travel and year-end gatherings increase the urgency of protection. The findings point to clear opportunities to strengthen public health, including empowering healthcare professionals as trusted messengers and promoting co-administration of vaccines.

time to read

4 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

No Funding No Vax for TB?

The World Health Organization (WHO)'s latest updates on tuberculosis (TB) released on November 12 reveal significant progress in diagnosis, treatment, and political commitment, but also expose deep vulnerabilities—especially in the South-East Asia Region (SEARO)—related to funding gaps and the uncertain future of novel TB vaccines. SEARO remains the global epicentre of the TB epidemic, carrying more than 45 per cent of the world's TB incidence despite representing only a quarter of the global population.

time to read

2 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Australia builds tailored heart pump to transform heart failure care

Despite making up half of the 64 million people living with heart failure, patients with this common form have no access to heart pump treatments and are left with only medication or palliative care.

time to read

1 min

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Clinical Research Trends 2026: Hybrid DCTs Set for Surge as Innovation Outpaces Regulatory Hurdles

APAC's openness to innovation, combined with its large population and low trial density, creates strong potential for expanding decentralised clinical trials (DCTs), especially for patients with limited trial access. While regulatory diversity and operational challenges will continue to hinder fully decentralised models, the region is expected to adopt more digital technologies in clinical research. As a result, hybrid DCTs will keep gaining traction, and effective management of digitally collected data will remain a central focus for data science teams.

time to read

4 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

CSL Seqirus to localise advanced influenza vaccine manufacturing in Saudi Arabia

Australia-based CSL Seqirus and Vaccine Industrial Company have signed a Memorandum of Understanding with the Ministry of Health of Saudi Arabia to enhance the biotechnology sector by accessing advanced cellbased seasonal and pandemic influenza vaccines and localising manufacturing in Saudi Arabia.

time to read

1 min

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

How Sponsors Could Gain Advantage by Embracing Dose Optimisation in Asia by 2026

In 2026, oncology drug development in Asia may move away from the historical maximum tolerated dose (MTD) paradigm toward evidence-based dose optimisation. Sponsors might consider adopting strategies similar to the FDA's Project Optimus, which emphasises selecting doses that balance efficacy and safety rather than relying solely on toxicity thresholds. Doing so could improve patient outcomes and position companies favourably as regulatory expectations evolve.

time to read

1 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Fujifilm launches joint research with National Cancer Center in Japan

Fujifilm Corporation has signed a joint research agreement with the National Cancer Center Japan, a Tokyo-based national institution recognised for its leadership in cancer care and research.

time to read

1 min

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Monash spinout RAGE Biotech secures $29 M to advance next-generation RNA therapeutics

Australia's Monash University spinout RAGE Biotech has raised $29 million in Series A funding, marking a major step toward translating RNA-based therapeutics for chronic inflammatory disease into the clinic.

time to read

1 min

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Submitting clinical data to the FDA and PDMA: An efficient and compliant approach

In both the US and Japan, regulators provide an extensive set of resources detailing the rules and specifications governing submissions for marketing approval of new drugs and biologics. Fortunately, despite some differences, the regulations concerning clinical data have a surprising amount in common. It is possible that with a solid understanding of the requirements and an adherence to best practices, sponsors can develop some of the same material for submission to both countries.

time to read

2 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Regenerative medicines and microbiome health are emerging as exciting frontiers, with Australian companies and researchers pushing into new therapeutic approaches

After more than a year at the helm of AusBiotech, CEO Rebekah Cassidy reflects on her early priorities and the organisation’s ambitions as Australia accelerates its position in the global life sciences economy. In an email interaction on the sidelines of AusBiotech 2025, she highlights the country's progress in mRNA, cell and gene therapy, and radiopharmaceuticals, outlines emerging areas of momentum, and discusses how new partnerships and MoUs are strengthening collaboration across the biotech ecosystem. Rebekah also outlines how AusBiotech is preparing Australia for a more competitive and connected global life sciences economy and the strategic priorities shaping AusBiotech’s next chapter. Edited excerpts:

time to read

7 mins

BioSpectrum Asia Dec 2025

Translate

Share

-
+

Change font size

Holiday offer front
Holiday offer back